Analyst Price Targets — RXST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:09 am | David Saxon | Needham | $13.00 | $8.81 | StreetInsider | Needham Reiterates Buy Rating on RxSight Inc. (RXST) |
| January 20, 2026 11:45 am | — | Piper Sandler | $11.00 | $9.81 | TheFly | RxSight price target raised to $11 from $10 at Piper Sandler |
| December 2, 2025 11:39 am | — | Morgan Stanley | $10.00 | $11.65 | TheFly | RxSight price target raised to $10 from $9 at Morgan Stanley |
| November 6, 2025 4:57 pm | — | Stifel Nicolaus | $10.00 | $8.73 | TheFly | RxSight price target raised to $10 from $8 at Stifel |
| October 29, 2024 8:11 am | Anthony Crowdell | Mizuho Securities | $67.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
| October 29, 2024 8:11 am | Curry Baker | Guggenheim | $52.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
| October 29, 2024 8:11 am | Adam Seiden | Barclays | $110.00 | $52.00 | Benzinga | This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday |
| October 29, 2024 3:09 am | Young Li | Jefferies | $72.00 | $50.25 | StreetInsider | Jefferies Starts RxSight Inc. (RXST) at Buy |
| September 23, 2024 5:33 am | Ryan Zimmerman | BTIG | $59.00 | $52.98 | StreetInsider | BTIG Reiterates Buy Rating on RxSight Inc. (RXST) |
| September 13, 2024 6:34 am | David Saxon | Needham | $66.00 | $54.54 | StreetInsider | Needham Reiterates Buy Rating on RxSight Inc. (RXST) |
Latest News for RXST
RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript
RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.03 per share a year ago.
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at…
Edap Tms (NASDAQ: EDAP - Get Free Report) and RxSight (NASDAQ: RXST - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Profitability This table compares Edap Tms and RxSight's
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RXST.
U.S. House Trading
No House trades found for RXST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.